Objective To assess repeatability and reproducibility of spirometry measurements, and bronchodilator responsiveness (BDR), in healthy 3-6-year-old preschool children and those with asthma. Design Spirometry was performed before and 20 minutes after administering either inhaled placebo (for repeatability) or 400 μg salbutamol (for BDR) on two separate occasions (reproducibility) 3-23 days apart in asthmatic preschoolers and healthy controls. Settings Lung Function Laboratory, Hospital de Dona Estefania, Lisbon. Participants Healthy preschool children and those with physician-diagnosed asthma, recruited from local Health Clinics and Outpatient Clinic. Results Technically successful baseline results were obtained in 86% of children assessed. Paired data were obtained in 43 asthmatic and 22 controls (median (range) age: 5.1 (3.4-6.8) years). Baseline FEV 0.75 was significantly lower in asthmatic children (mean (SD): 90 (15)% predicted) than in controls (102 (13) % predicted; p<0.001). Withinoccasion coefficient of repeatability following placebo was similar in both groups, being 10.4% in asthma and 13.2% in controls for FEV 0.75 . Following bronchodilator, FEV 0.75 increased significantly more in asthmatic preschoolers (mean (SD): 15.0 (12) %) than in controls (4.5 (5) %; p<0.001), with no significant difference between groups post-bronchodilator. Between-occasion variability was similar to within-day repeatability in controls, but almost twice as high in asthmatic children. Conclusions BDR can be assessed reliably using FEV 0.75 in wheezy preschoolers, provided within-subject variability and responsiveness in health are taken into consideration.
INTRODUCTION
The prevalence of asthma varies with 4.1%-26.7% of Western European preschool children (aged 5-6 years) being affected (9.6% in Portugal). 1 Many children with recurrent wheeze tend to outgrow their symptoms, whereas others wheeze persistently throughout adulthood. The diagnosis and treatment of asthma in young children may be challenging to the clinician 2 3 and mild intermittent asthma is often misdiagnosed. [4] [5] [6] [7] Since clinical symptoms alone may be insufficient for diagnosis, more objective assessments of airway obstruction have been recommended. 8 In older subjects, pulmonary function tests (PFTs) are an integral part of the management of respiratory disease contributing towards diagnosis, prognosis, monitoring of disease evolution and evaluating effects of therapeutic interventions. During recent years, it has been shown that most preschool children ( preschoolers) can also perform these tests if adequately motivated and supervised. [9] [10] [11] [12] American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines 8 and improved reference equations for such tests are now available for this age group. 13 Standardised measurements of bronchodilator responsiveness (BDR) using spirometry are well established for older subjects, a positive response usually being defined when forced expired volume in 1 s (FEV 1 ) increases by at least 12% and 200 ml, [14] [15] [16] [17] but the extent to which this applies to young children remains unclear. 3 8 Despite increasing use of PFTs in preschoolers to assess both baseline values and bronchial responsiveness, interpretation of results in this age group is often limited by the lack of knowledge regarding within-and between-occasion variability 3 8 and the extent to which healthy children of similar age respond to bronchodilators. [18] [19] [20] [21] What is already known on this topic ▸ Spirometric assessment of bronchodilator responsiveness is important when diagnosing asthma but its usefulness in preschool children has yet to be established. ▸ Recent introduction of guidelines and quality control criteria for preschool children have facilitated accurate assessments of spirometry in children as young as 3 years of age.
What this study adds
▸ This study demonstrates that in wheezy preschool children (aged 3-6 years), bronchodilator responsiveness can be assessed reliably using spirometry to assist diagnosis and potentially guide and evaluate therapeutic interventions. ▸ An understanding of within-subject variability and responsiveness in health should be considered when interpreting results.
This study aimed to assess the within-day repeatability and between-occasion reproducibility of spirometric outcomes in preschoolers with physician-diagnosed asthma and healthy controls, and compare response to bronchodilator between these groups.
METHODS Subjects
Preschool children, aged 3-6 years, with mild to moderate asthma diagnosed by a physician specialised in immunoallergy 5 22 were recruited from the Outpatient Clinic at the Hospital Dona Estefania, Lisbon (March 2006 to March 2009). Healthy preschoolers who had been born full-term with appropriate birth weight and without any significant prior medical history including lower respiratory illness, wheeze or allergic disorders (food allergy, eczema) or parental asthma were recruited from local Health Clinics.
Ethics Committee approval was obtained, and parents of participating children gave informed written consent.
Pulmonary function tests
All measurements were undertaken by the same technician in Lisbon, where equipment was calibrated daily according to the manufacturer's instructions. At time of assessments, all children had been free of any respiratory symptoms for at least 3 weeks. In asthmatic children, bronchodilators were withheld for at least 48 h. 23 Weight and height were measured using digital scales and a calibrated stadiometer. Baseline spirometry was assessed using the MasterScreen Body Jaeger spirometer (V.4.65, Jaeger, San Diego, USA) according to recent international guidelines 8 10 with the child seated and wearing nose clips. Using a cross-over design, children were then allocated (using alternate randomisation) to receive either placebo (to assess repeatability) or salbutamol (400 μg via an aerochamber) to assess BDR. The children, their parents and the investigator who analysed lung function results were blinded to the treatment. The placebo consisted of a hydrofluorocarbons (HFC) propellant-only inhaler (without active drug).
Provided subjects remained clinically stable (ie, no exacerbations or respiratory infections), all children were invited to return for a second visit within 3 weeks of the first test occasion when, following repeated baseline measurements, they were administered the alternative inhalation agent. Technically acceptable data 8 10 obtained in children who successfully completed all four sets of measurements form the basis of this report. All PFT values were expressed as z-scores, which adjust for sex, age and height. 13 24 Sample size and statistical analysis Given the need for families to attend twice within a month, it was anticipated that recruitment of healthy children would be more difficult than those with asthma. Power calculations were therefore based on uneven groups. It was estimated that complete datasets in 40 asthmatics and 20 controls would provide 80% power to detect a difference of 0.8 z-scores between asthmatics and controls at the 5% significance level for the selected outcome variables. 25 When examining within-subject differences (ie, change in lung function following either placebo or salbutamol on the same day, or differences in baseline measurements between two occasions), there would be 80% power to detect a within-subject difference of 0.45 z-scores with 20 subjects in each group. This equates to a change of approximately 6% for forced expired volume in 0.75 s (FEV 0.75 ), 7% for forced vital capacity (FVC) and 18% for forced expiratory flow between 25% and 75% of the FVC (FEF ). 13 Comparisons of demographic details and lung function between study groups were performed using independent sample t tests (when data were normally distributed) with 95% CI and tests for proportions.
Within-subject differences were assessed using paired t tests and limits of agreement were derived as mean within-subject difference ±1.96 times the SD of the difference. 26 The within-occasion between-measurement coefficient of repeatability following a placebo (CR w ) was calculated as twice the SD of the within-subject difference between two measurements (expressed as a percentage) following administration of an inhaled placebo. CR w is conventionally assessed by comparing the relative difference between two sets of measurements on the same occasion under identical conditions that are simply separated by an appropriate interval. 8 27 However, inhalation of a placebo was included in the study protocol to ensure that use of the inhaler per se did not inflate the variability or apparent response to bronchodilator. The between-occasion coefficient of reproducibility (CR b ) was calculated as twice the SD of the within-subject percentage difference between two baseline measurements within a 3-week period. 8 All analyses were performed in Stata (V.10.0, Texas, USA). Graphs were created using GraphPad Prism (V.5, San Diego, USA).
RESULTS

Population characteristics
Consent was obtained for 91% of the eligible index children from the asthma clinic, of whom 86% (43/50) successfully completed the full study protocol (figure 1). At the time of assessments, asthmatic children were clinically stable and receiving regular asthma treatment, with 84% (36/43) receiving inhaled corticosteroids. Of the 90 families of healthy children approached, 38 (42%) consented, of whom 87% had successful baseline spirometry. Of these 58% (22/38) completed the study. Lack of parental consent for bronchodilation (24%) was the major reasons for attrition among the healthy controls (figure 1). Success rates for obtaining technically satisfactory spirometry were similar between the groups, but successful results were associated with increasing age of the child (32/48 (67%) <4 years vs 33/40 (83%) 4-6-year-olds).
The population characteristics for those completing the study protocol are presented in table 1. There were no significant differences between groups with respect to birth characteristics, sex, age or weight at time of test, although asthmatic children were slightly taller than controls. A large proportion of children in both groups were exposed to environmental tobacco smoke, especially in those with asthma. As expected, prevalence of family history of atopy was higher among the asthmatic children.
Comparison of baseline pulmonary function results at first visit Up to 15 forced expiratory flow-volume manoeuvres were obtained (median (range): 5 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] ) from each child during each of the four measurement sessions from which the best curve was selected. At the first test occasion, baseline measurements of z-FEV 0.75 , z-FEV 1 and z-FEF were significantly lower in asthmatic children than the controls (table 2) .
Within-occasion repeatability (CR w ): effect of placebo
There were no significant group changes in any of the lung function outcomes in response to the placebo inhaler in either the controls or those with asthma ( figure 2, table 3(a) ).
Nevertheless, changes within individuals could be considerable; the mean within-occasion coefficient of repeatability (CR w ; ie, twice the SD of within-subject changes) for FEV 0.75 being 10.4% in asthmatic and 13.2% in healthy children and considerably higher for FEF (table 3(a) ).
Bronchodilator responsiveness
Differences in baseline spirometry between healthy and asthmatic preschoolers were no longer evident post bronchodilator (table 2). After salbutamol was administered to the healthy controls, there were significant improvements (relative change from baseline) in FEV 0.75 , FEV 1 and FEF , whereas FVC was unchanged (table 3(b) ). Among those with asthma, all outcomes improved significantly after administration of salbutamol. With the exception of FVC, asthmatic children demonstrated significantly larger bronchial responsiveness compared with controls (table 3(b), figure 2), the most marked difference in BD response between groups being seen for FEV 0.75 . The interpretation of results remained the same whether using relative change from baseline or change on the z-score scale.
How much change in response to bronchodilator is clinically significant? Based on our sample of 22 healthy controls, the threshold for a positive BDR (ie, mean difference + 2SD following placebo) using spirometry would be an increase of 14% for FEV 0.75 or FEV 1 or 33% for FEF to be outside the range of variability observed in response to placebo. 
Variability of lung function between occasions (reproducibility)
Repeat measurements were performed 3-23 (median 7) days after the first visit for asthmatic children and 3-13 (median 6) days for the controls. In both groups, mean results for all outcomes were similar on both test occasions. There were no significant changes in any lung function outcome over this period in either group. In contrast to healthy controls in whom variability between occasions (CR b ) was very similar to that observed between tests within the same day (CR w ) (being approximately 13% (1.0 z-score) for FEV 0.75 and 34% (1.4 z-scores) for FEF ), the CR b for all spirometric outcomes was up to twice as high as the CR w in asthmatic children and approximately double that seen in health (CR b for asthmatic children being 26% and 45% for FEV 0.75 and FEF , respectively).
DISCUSSION
This study demonstrates the feasibility of assessing BDR in using spirometry in 3-6-year-olds, with 86% providing technically acceptable baseline measurements, and the majority successfully completing paired measurements. The results also provide important new information for this age group regarding withinand between-test variability of lung function in those with doctor-diagnosed asthma when compared with their healthy peers. Results suggest that a large proportion of healthy preschoolers show some response to bronchodilators, that the magnitude of response varies widely according to outcome and that commonly used thresholds of 10% or 12% for indicating a positive BDR when using FEV 1 or FEV 0.75 may be inappropriate in such children. In this study, the threshold for a positive BDR (ie, mean difference + 2SD following placebo) using spirometry was an increase of 14% for FEV 0.75 or FEV 1 or 33% for FEF . Using these cut-offs, 18/43 (42%) children with asthma would have been classified as 'responders' for FEV 0.75 , 12/37 (32%) for FEV 1 , and 20/43 (47%) for FEF . Given the relatively small sample size, these results will however need to be verified in a larger study.
Galant et al reported in two studies 14 15 that 33% and 44% of asthmatic children, respectively, had a BD response >10% above baseline values. The main difference in the findings between our study and others 14 19 is the magnitude of BDR response: that is, a 9% threshold was previously reported for positive bronchodilation, which is considerably lower than findings in our study; they also tested slightly older children (4-7 years) and reported FEV 1 as their primary outcome whereas 50% of children in our study were <4 years of age.
Despite increasing success in obtaining spirometric measurements in preschoolers, 8 12 13 19 28-32 it has been suggested that this may not be a feasible tool to assess BDR in this age group. 8 33 Many authors have therefore selected alternative Table 2 Comparison of: (a) baseline and (b) postbronchodilator results in 43 children with asthma and 22 healthy controls Results are expressed as mean (SD) z-scores which adjust for sex, height and age at time of testing. 13 Text in italic indicates significant differences between groups; figure 2 shows these results expressed as % change rather than z-scores. *p<0.05; **p<0.01; ***p<0.001.
†FEV 1 : n=42 for asthma and 19 for controls due to forced expiratory time being <1 s in the remaining four children. FEF , forced expiratory flow between 25% and 75% of the forced vital capacity; FEV 0.75 , forced expired volume in 0.75 s; FEV 1 , forced expired volume in 1 s; FVC, forced vital capacity. Figure 2 Relative change in lung function in response to placebo and bronchodilator in healthy controls and asthmatic preschool children. BD, bronchodilator; HC, healthy controls. Open and closed circles=% change preplacebo and postplacebo in healthy controls and asthmatic preschool children; open and closed triangles=% change prebronchodilator and postbronchodilator in healthy controls and asthmatic preschool children. The p values indicate differences in response to placebo or bronchodilator between groups and between interventions. FEF , forced expiratory flow between 25% and 75% of the forced vital capacity; FEV 0.75 , forced expired volume in 0.75 s.
techniques such as the interrupter or forced oscillation technique that requires less subject cooperation. 18 33-37 However, in keeping with other recent results, 19 38 this study demonstrated that provided a suitable child-friendly environment is available, staff are intensively trained and there is strict adherence to appropriate quality control criteria, a high success rate for acceptable spirometric measurements can be obtained in preschoolers both prebronchodilator and postbronchodilator, with less variability within and between subjects than that observed for lung function tests that require less subject cooperation. 18 37 39 Despite its potential usefulness, assessing bronchial responsiveness can be fraught with problems at any age, including which test or outcome to use, which dose of bronchodilator to administer, what threshold best discriminates between subjects and how best to express results. 8 17-19 31 34-36 40 41 The strengths of this study include prospective recruitment of healthy controls of similar age with whom to compare BDR. Reliance on BDR thresholds established for older subjects would have resulted in considerable overdiagnosis in these younger children, since 15% of healthy preschoolers had a postbronchodilator increase in FEV 1 >12% (rising to 25% had a threshold of 10% increase been used).
The sample included 91% of asthmatic children who presented at our clinic but had excluded children with a previous hospitalisations and severe asthma were excluded. Consequently, the population studied does not represent the entire spectrum of preschoolers with asthma. Since estimates of the proportion of asthmatic children detected using any proposed post-BD cut-off will always be influenced by the selection criteria applied, caution is required when comparing results between studies. Establishment of appropriate thresholds for BDR which take into account both the response in healthy children and within-occasion variability is an important prerequisite when designing studies to ascertain either the degree of BDR according to disease severity or response to alternative types of therapy.
In this study, background characteristics of both groups were similar, except for family history of atopy which was, as expected, higher in the asthmatics. A very high exposure to environmental tobacco smoke was documented in both groups. Despite recent concerted efforts to reduce tobacco smoking in Portugal, the prevalence remains high (up to 45% in men between 35 and 44 years of age), 42 consistent with that found in this study. While this could potentially limit the extent to which results are generalisable to countries where the incidence of passive smoke exposure is lower, the fact that baseline results from the healthy controls were so close to predicted values (being within 5% or 0.3 z-scores for all reported outcomes) suggests that this may not be the case.
Additional strengths of the study included assessing the variability of measurements at intervals relevant to the intended uses of the tests, which included within-occasion repeatability with which to interpret response to BD as well as variability over a matter of days or weeks which could be relevant in clinical management or used as objective outcomes in clinical trials. Of particular importance was the finding that, despite the lack of any significant mean change in any outcome in either group over a period of several weeks, the within-subject variability between test occasions in asthmatic children was double that observed in their healthy counterparts, despite the fact that they were studied during periods of clinical stability and without any change in therapy.
CONCLUSIONS
BDR can be assessed reliably using spirometry in wheezy 3-6-year-olds, provided that the technique is suitably adapted for this age group and both within-subject variability and responsiveness in health are taken into consideration. It is recommended that FEV 0.75 is used as a primary outcome when assessing BDR in this age group since it appears to be a more discriminative outcome at this age. 
